Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

Butchart, J., Brook, L., Hopkins, V., Teeling, J., Puntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, Rachel, Thomas, Rhodri ORCID: https://orcid.org/0000-0003-2841-9682, Passmore, P., Perry, V. H. and Holmes, C. 2015. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 84 (21) , pp. 2161-2168. 10.1212/WNL.0000000000001617

Preview

PDF - Published Version Download (512kB) | Preview

Abstract

Objectives: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. Methods: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT (2009-013400-31) and ClinicalTrials.gov (NCT01068353). Results: Forty-one participants (mean age 72.4 years; 61% men) were randomized to etanercept (n = 20) or placebo (n = 21). Etanercept was well tolerated; 90% of participants (18/20) completed the study compared with 71% (15/21) in the placebo group. Although infections were more common in the etanercept group, there were no serious adverse events or new safety concerns. While there were some interesting trends that favored etanercept, there were no statistically significant changes in cognition, behavior, or global function. Conclusions: This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of patients. Classification of evidence: This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in Alzheimer disease dementia.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Publisher:	American Academy of Neurology
ISSN:	0028-3878
Date of First Compliant Deposit:	18 November 2019
Date of Acceptance:	15 February 2015
Last Modified:	04 May 2023 23:27
URI:	https://orca.cardiff.ac.uk/id/eprint/80696

Citation Data

Cited 162 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item